PRTA (Prothena Corporation plc) Stock Financials & Earnings | Market Cap Arena

PRTA (Prothena Corporation plc) Stock Financials & Earnings | Market Cap Arena

PRTAProthena Corporation plc

Mkt Cap$549M

Healthcare·Biotechnology·🇮🇪 Ireland·NASDAQ

Revenue (TTM)$10M

Net Income (TTM)-$244M

EPS (TTM)-$4.54

Free Cash Flow (TTM)-$168M

Gross Margin-208.6%

Op. Margin-2247.5%

Net Margin-2520.6%

FCF Margin-1730.4%

P/S Ratio (TTM)56.6x

P/E Ratio (TTM)—

YoY Rev Growth-92.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$2M	-$43M	-$56M
Q2 23	$4M	-$52M	-$67M
Q3 23	$85M	$27M	$10M
Q4 23	$316K	-$62M	-$79M
Q1 24	$50K	$50K	-$82M
Q2 24	$132M	$132M	$58M
Q3 24	$970K	$970K	-$67M
Q4 24	$2M	$2M	-$65M
Q1 25	$3M	$3M	-$66M
Q2 25	$4M	$4M	-$85M
Q3 25	$2M	-$27M	-$40M
Q4 25	$21K	-$921K	-$27M

Valuation

Quarter	P/S	P/E
Q1 23	10.0x	—
Q2 23	9.5x	—
Q3 23	3.9x	—
Q4 23	6.0x	—
Q1 24	6.1x	—
Q2 24	2.5x	—
Q3 24	4.1x	—
Q4 24	4.1x	—
Q1 25	4.0x	—
Q2 25	53.0x	—
Q3 25	46.5x	—
Q4 25	56.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$47M	-$48M
Q2 23	-$45M	-$46M
Q3 23	$10M	$9M
Q4 23	-$51M	-$53M
Q1 24	-$73M	-$73M
Q2 24	$16M	$16M
Q3 24	-$45M	-$45M
Q4 24	-$48M	-$48M
Q1 25	-$53M	-$53M
Q2 25	-$46M	-$46M
Q3 25	-$41M	-$41M
Q4 25	-$27M	-$27M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$48K
Q2 23	$771K
Q3 23	$442K
Q4 23	$2M
Q1 24	$103K
Q2 24	$143K
Q3 24	$9K
Q4 24	$43K
Q1 25	$42K
Q2 25	$86K
Q3 25	$10K
Q4 25	$5K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+88.1%	+49.6%
Q2 23	+206.3%	+58.4%
Q3 23	+5494.3%	+43.8%
Q4 23	-99.4%	+57.7%
Q1 24	-97.7%	+39.5%
Q2 24	+3184.7%	+4.4%
Q3 24	-98.9%	-9.5%
Q4 24	+571.8%	-15.0%
Q1 25	+5556.0%	-16.1%
Q2 25	-96.7%	+20.9%
Q3 25	+149.0%	-36.8%
Q4 25	-99.0%	-59.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$9M	405.3%
Q2 23	$10M	251.3%
Q3 23	$11M	12.9%
Q4 23	$11M	3506.3%
Q1 24	$12M	24766.0%
Q2 24	$12M	9.1%
Q3 24	$11M	1136.1%
Q4 24	$11M	495.5%
Q1 25	$11M	387.2%
Q2 25	$12M	281.0%
Q3 25	$7M	298.1%
Q4 25	$7M	33685.7%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$45M	$14M
Q2 23	$56M	$15M
Q3 23	$58M	$17M
Q4 23	$62M	$17M
Q1 24	$64M	$17M
Q2 24	$58M	$16M
Q3 24	$51M	$17M
Q4 24	$50M	$17M
Q1 25	$51M	$18M
Q2 25	$41M	$16M
Q3 25	$29M	$13M
Q4 25	$15M	$13M

Revenue Segments

Quarter	Collaboration	License
Q4 23	$316K	—
Q1 24	—	$50K
Q2 24	$132M	—
Q3 24	$970K	—
Q1 25	$3M	$50K
Q2 25	$4M	—
Q3 25	$2M	—
Q4 25	$21K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$686M	$0	$686M
Q2 23	$659M	$0	$659M
Q3 23	$671M	$0	$671M
Q4 23	$619M	$0	$619M
Q1 24	$547M	$0	$547M
Q2 24	$564M	$0	$564M
Q3 24	$519M	$0	$519M
Q4 24	$471M	$0	$471M
Q1 25	$418M	$0	$418M
Q2 25	$371M	$0	$371M
Q3 25	$331M	$0	$331M
Q4 25	$308M	$0	$308M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	53M	-2.7%
Q2 23	53M	+1.2%
Q3 23	58M	+9.2%
Q4 23	54M	-7.5%
Q1 24	54M	+0.1%
Q2 24	55M	+2.5%
Q3 24	54M	-2.3%
Q4 24	54M	+0.0%
Q1 25	54M	+0.0%
Q2 25	54M	+0.0%
Q3 25	54M	+0.0%
Q4 25	54M	+0.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$1M	46
FY 15	$24K	66
FY 16	$11K	96
FY 17	$220K	125
FY 18	$16K	59
FY 19	$16K	51
FY 20	$13K	66
FY 21	$2M	82
FY 22	$424K	127
FY 23	$528K	173
FY 24	$829K	163
FY 25	$97K	100